SCHEMBL250898

SCHEMBL250898

O=C(Cl)N=C=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30530530 0.72
SCHEMBL483875 0.72
SCHEMBL840800 0.69
Water SCHEMBL28177570 0.69
SCHEMBL7834439 0.69
SCHEMBL127085 0.69
SCHEMBL3822372 0.67
SCHEMBL3177330 0.67
SCHEMBL11674193 0.67
SCHEMBL23611178 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3858387-A1 MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS Seagen Inc. (US) 2021-08-04 EP disclosed
EP-3778917-A2 MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS, AND METHODS F. Hoffmann-La Roche AG (CH) 2021-02-17 EP disclosed
US-10918735-B2 Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-02-16 US disclosed
US-20200347149-A1 MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS SEAGEN INC. 2020-11-05 US disclosed
US-10808039-B2 Monomethylvaline compounds capable of conjugation to ligands SEATTLE GENETICS INC. (US) 2020-10-20 US disclosed
US-10584181-B2 Methods of making and using multispecific antibody panels and antibody analog panels GENENTECH, INC. (US) 2020-03-10 US disclosed
US-20190338045-A1 MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS SEAGEN INC. 2019-11-07 US disclosed
US-10414826-B2 Monomethylvaline compounds capable of conjugation to ligands SEATTLE GENETICS, INC. (US) 2019-09-17 US disclosed
US-20190255187-A1 SUBSTITUTED PYRAZINO[1',2':1,5]PYRROLO[2,3-B]INDOLE-1,4-DIONES FOR CANCER TREATMENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-08-22 US disclosed
EP-3505191-A1 AURISTATINS HAVING AN AMINOBENZOIC ACID UNIT AT THE N TERMINUS Seattle Genetics, Inc. (US) 2019-07-03 EP disclosed
US-20060074008-A1 monoclonal antibody conjugated with peptide drug such as dolastatin derivative SEAGEN INC. 2006-04-06 US disclosed
WO-2006034488-A2 CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES GENENTECH, INC. (US) 2006-03-30 WO disclosed
US-20050238649-A1 Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases SEATTLE GENETICS, INC. (US) 2005-10-27 US disclosed
WO-2005081711-A2 MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS SEATTLE GENETICS, INC. (US) 2005-09-09 WO disclosed
EP-1545613-A2 DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE Seattle Genetics, Inc. (US) 2005-06-29 EP disclosed
WO-2004010957-A2 DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE SEATTLE GENETICS, INC. (US) 2004-02-05 WO disclosed
EP-1147096-A1 HERBICIDAL OXADIAZOLIDINES E. I. du Pont de Nemours and Company (US) 2001-10-24 EP disclosed
WO-2000043377-A1 HERBICIDAL OXADIAZOLIDINES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2000-07-27 WO disclosed
EP-0220899-B1 BIFUNCTIONAL LINKER Immunomedics, Inc. (US) 1992-03-11 EP disclosed
US-4680338-A Bifunctional linker IMMUNOMEDICS, INC. (US) 1987-07-14 US disclosed